NOL

Engaged Capital Sends Letter to Board of Quotient Technology Inc.

Quotient, Charter, Board of directors, Internal Revenue Code, Adoption, Capital, Time, Acquisition, Company, EBITDA, NYSE, IPO, Solution, Ability, Letter, Annual general meeting, Investment, GLOBE, LLC, Board, NOL, Rois, 2021 Buckinghamshire Council election, Chief, Security (finance), Holding company, Risk management, Management, Fine chemical

The full text of the letter follows:

Key Points: 
  • The full text of the letter follows:
    Engaged Capital, LLC (Engaged, us, or we) has been a significant stockholder in Quotient Technology Inc. (QUOT or the Company) since October 2020.
  • In addition to the Companys operational struggles, we are alarmed by the Board of Directors (the Board) blatant disregard for good governance and dereliction of fiduciary duties to stockholders.
  • Rather than taking decisive action to remedy the weak operating and share price underperformance, the Board has selfishly focused on employing strategies to further entrench itself.
  • While having a classified Board is bad enough, the Board manipulated the classes on which directors serve to further limit stockholders say on the composition of the Board.

CorMedix Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Dienstag, November 9, 2021
Nexus, NDA, Society, Mortality, Corporation, American Society of Nephrology, AMCP, Industry, CMO, Leadership, NOL, CEO, Disease, Hand, Investment, 2021 Essex County Council election, Board, Association, Incidence, Company, GLOBE, Infection, Compliance, Bloodstream infections, EVP, ASN, Nasdaq, Patient, Marketing, General counsel, Pharmaceutical industry, Cryptocurrency

CorMedix continues to work diligently toward the resubmission of the DefenCath NDA and plans to provide an update when we have clarity on the submission timeline.

Key Points: 
  • CorMedix continues to work diligently toward the resubmission of the DefenCath NDA and plans to provide an update when we have clarity on the submission timeline.
  • CorMedix announced in October that its Board had appointed Matt David M.D., CorMedixs EVP and Chief Financial Officer, as interim Chief Executive Officer.
  • Operating expenses in the third quarter of 2021 increased approximately 30% to $8.6 million, compared with $6.6 million in the third quarter of 2020.
  • The management team of CorMedix will host a conference call and webcast today, November 9, 2021, at 4:30 PM Eastern Time, to discuss recent corporate developments and financial results.

Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses

Retrieved on: 
Montag, November 8, 2021
Transfer, NOLS, Phase, Secretary of State of New Jersey, Private Securities Litigation Reform Act, News, NOL, NASDAQ, RNA, Technology, Failure, Ovarian cancer, Capital, Investment, Growth, Immunotherapy, Research, Workforce, New Jersey Economic Development Authority, Forward-looking statement, FDA, Program, Sale, Biotechnology, Company, GLOBE, U.S. Securities and Exchange Commission, Progression-free survival, Doxorubicin, Time, DNA, PFS, Risk, Drug development, Pharmaceutical industry

LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced it was notified by the New Jersey Economic Development Authority (NJEDA) that the Company’s application to sell $1.5 million of its unused New Jersey net operating losses (NOLs) for the tax year 2020 under the Technology Business Tax Certificate Transfer (NOL) program has been approved the NJEDA’s Board of Directors. The Company anticipates it will be able to transfer this credit to a qualified company and receive approximately $1.4 million of net cash proceeds. With this additional funding, the Company expects to report over $62 million in cash and investments at end of the third quarter ended September 30, 2021.

Key Points: 
  • The Company anticipates it will be able to transfer this credit to a qualified company and receive approximately$1.4 millionof net cash proceeds.
  • With this additional funding, the Company expects to report over$62 millionin cash and investments at end of the third quarter endedSeptember 30, 2021.
  • With theNew Jersey State Legislatureincreasing the maximum lifetime benefit per company from$15 millionto$20 million, this has allowed Celsion to continue participating in this innovative funding program, saidMichael H. Tardugno, Celsion Corporations chairman, president and chief executive officer.
  • Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19

Retrieved on: 
Donnerstag, Oktober 28, 2021
Inhalation, TFF, Infection, Lung, SAD, MAD, Volunteering, University, Solubility, GLP, Single, Disease, IV, BID, UNION, Human, Dry-powder inhaler, Partnership, Patient, NASDAQ, FDA, Food, Health Canada, RATS, Severe acute respiratory syndrome coronavirus 2, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Annual report, Niclosamide, NOL, Company, Critical Care Medicine (journal), Absorption, CEO, COVID-19, Microbiology, Pharmacokinetics, Therapy, Toxicity, GLOBE, Viral load, Pharmaceutical industry

AUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has received approval from Health Canada to begin a Phase 1 clinical trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other infectious diseases.

Key Points: 
  • The Phase 1 study was cleared by Health Canada via a No Objection Letter (NOL) received on October 22, 2021.
  • TFF Pharmaceuticals anticipates the first patient will be dosed in the study in November and that enrollment will be completed by early Q1 2022.
  • We believe that our preclinical results for inhaled niclosamide will translate to positive outcomes in humans and look forward to initiating the study.
  • Food and Drug Administrationfor use in humans in 1982, niclosamide is an oral anthelmintic drug and is included in theWorld Health Organization'slist of essential medicines1.

Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker

Retrieved on: 
Dienstag, September 7, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Diabetes, Clinical Trials, INV-202, Inversago Pharma, INV-202, INVERSAGO PHARMA

Having demonstrated pharmacological characteristics that exceeded our expectations during IND-enabling preclinical studies, were excited to launch a second peripherally-acting CB1 blocker into the clinic with INV-202, said Dr. Glenn Crater, MD, Chief Medical Officer of Inversago Pharma.

Key Points: 
  • Having demonstrated pharmacological characteristics that exceeded our expectations during IND-enabling preclinical studies, were excited to launch a second peripherally-acting CB1 blocker into the clinic with INV-202, said Dr. Glenn Crater, MD, Chief Medical Officer of Inversago Pharma.
  • INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions.
  • The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
  • Headquartered in Montreal, Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.

CorMedix Inc. Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, August 12, 2021
Transfer, Net, Hand, Letter, Company, NOL, GLOBE, NDA, FDA, Marketing, Patient, Investment, Sale, Nasdaq, Pharmaceutical industry

For the second quarter 2021, CorMedix recorded a net loss of $4.6 million, or $0.12 per share, compared with a net loss of $3.8 million, or $0.14 per share, in the second quarter of 2020.

Key Points: 
  • For the second quarter 2021, CorMedix recorded a net loss of $4.6 million, or $0.12 per share, compared with a net loss of $3.8 million, or $0.14 per share, in the second quarter of 2020.
  • Operating expenses in the second quarter of 2021 decreased approximately 34% to $5.9 million, compared with $8.9 million in the second quarter of 2020.
  • SG&A expense increased approximately 4% to $3.4 million compared with $3.2 million in the second quarter of 2020.
  • The management team of CorMedix will host a conference call and webcast today, August 12, 2021, at 4:30 PM Eastern Time, to discuss recent corporate developments and financial results.

SDRL: Seadrill Limited Announces Settlement agreement with Northern Ocean Ltd.

Retrieved on: 
Montag, August 9, 2021
OTC Markets Group, Kolskaya (jack-up rig), Chapter 11, Title 11, United States Code, Lundin, News, Court, NOL, Bankruptcy, Nature, Security (finance), Disclosure, Company, Risk management

HAMILTON, Bermuda, Aug. 9, 2021 /PRNewswire/ -- Seadrill Limited ("Seadrill" or "the Company") (OSE: SDRL) (OTCPK: SDRLF) announces that the Company has reached a settlement agreement with Northern Ocean Ltd. ("NOL") predominantly with respect to balances outstanding from Seadrill's preparation of the West Mira and West Bollsta rigs.

Key Points: 
  • HAMILTON, Bermuda, Aug. 9, 2021 /PRNewswire/ -- Seadrill Limited ("Seadrill" or "the Company") (OSE: SDRL) (OTCPK: SDRLF) announces that the Company has reached a settlement agreement with Northern Ocean Ltd. ("NOL") predominantly with respect to balances outstanding from Seadrill's preparation of the West Mira and West Bollsta rigs.
  • The settlement agreement closes all outstanding balances, claims and counter-claims between the companies and their respective subsidiaries by way of set-off as full and final settlement.
  • The settlement agreement is subject to certain conditions, including, but not limited to, obtaining approval by the US bankruptcy court under Seadrill's Chapter 11 protection.
  • Seadrill is a leading offshore drilling contractor utilizing advanced technology to unlock oil and gas resources for clients across harsh and benign locations across the globe.

SDRL: Seadrill Limited Announces Settlement agreement with Northern Ocean Ltd.

Retrieved on: 
Montag, August 9, 2021
OTC Markets Group, Kolskaya (jack-up rig), Chapter 11, Title 11, United States Code, Lundin, News, Court, NOL, Bankruptcy, Nature, Security (finance), Disclosure, Company, Risk management

HAMILTON, Bermuda, Aug. 8, 2021 /PRNewswire/ -- Seadrill Limited ("Seadrill" or "the Company") (OSE: SDRL) (OTCPK: SDRLF) announces that the Company has reached a settlement agreement with Northern Ocean Ltd. ("NOL") predominantly with respect to balances outstanding from Seadrill's preparation of the West Mira and West Bollsta rigs.

Key Points: 
  • HAMILTON, Bermuda, Aug. 8, 2021 /PRNewswire/ -- Seadrill Limited ("Seadrill" or "the Company") (OSE: SDRL) (OTCPK: SDRLF) announces that the Company has reached a settlement agreement with Northern Ocean Ltd. ("NOL") predominantly with respect to balances outstanding from Seadrill's preparation of the West Mira and West Bollsta rigs.
  • The settlement agreement closes all outstanding balances, claims and counter-claims between the companies and their respective subsidiaries by way of set-off as full and final settlement.
  • The settlement agreement is subject to certain conditions, including, but not limited to, obtaining approval by the US bankruptcy court under Seadrill's Chapter 11 protection.
  • Seadrill is a leading offshore drilling contractor utilizing advanced technology to unlock oil and gas resources for clients across harsh and benign locations across the globe.